高级检索
当前位置: 首页 > 详情页

Cell cycle duration determines oncogenic transformation capacity

文献详情

资源类型:
Pubmed体系:

收录情况: ◇ 自然指数

机构: [1]Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada. [2]Department of Ophthalmology and Visual Science, University of Toronto, Toronto, Ontario, Canada. [3]Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. [4]Department of Ophthalmology, Research Laboratory of Ophthalmology and Vision Sciences, Eye Research Institute, West China Hospital, Sichuan University, Chengdu, China. [5]CancerCare Manitoba Research Institute and Department of Pharmacology and Therapeutics, University of Manitoba, Winnipeg, Manitoba, Canada. [6]Donald K. Johnson Eye Institute, Krembil Research Institute, University Health Network, Department of Physiology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. [7]Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada. [8]Department of Developmental and Molecular Biology, The Albert Einstein Comprehensive Cancer Center and Liver Research Center, Albert Einstein College of Medicine, Bronx, NY, USA. [9]Department of Ophthalmology and Visual Sciences, The Albert Einstein Comprehensive Cancer Center and Liver Research Center, Albert Einstein College of Medicine, Bronx, NY, USA. [10]Department of Medicine, The Albert Einstein Comprehensive Cancer Center and Liver Research Center, Albert Einstein College of Medicine, Bronx, NY, USA. [11]Molecular Mechanisms of Cancer Program, Centro de Investigacion del Cancer, Consejo Superior de Investigaciones Cientificas (CSIC)-University of Salamanca, Salamanca, Spain. [12]Molecular Oncology Program, National Center for Cancer Research (CNIO), Madrid, Spain. [13]Division of Pathology and Laboratory Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. [14]The Perinatal Institute Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. [15]Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
出处:
ISSN:

摘要:
Oncogenic mutations are widespread in normal human tissues1. Similarly, in murine chimeras, cells carrying an oncogenic lesion contribute normal cells to adult tissues without causing cancer2-4. How lineages that escape cancer via normal development differ from the minority that succumb is unclear. Tumours exhibit characteristic cancer hallmarks; we therefore searched for hallmarks that differentiate cancer-prone lineages from resistant lineages. Here we show that total cell cycle duration (Tc) predicts transformation susceptibility across multiple tumour types. Cancer-prone Rb- and p107-deficient retina (Rb is also known as Rb1 and p107 is also known as Rbl1) exhibited defects in apoptosis, senescence, immune surveillance, angiogenesis, DNA repair, polarity and proliferation. Perturbing the SKP2-p27-CDK2/CDK1 axis could block cancer without affecting these hallmarks. Thus, cancer requires more than the presence of its hallmarks. Notably, every tumour-suppressive mutation that we tested increased Tc, and the Tc of the cell of origin of retinoblastoma cells was half that of resistant lineages. Tc also differentiated the cell of origin in Rb-/- pituitary cancer. In lung, loss of Rb and p53 (also known as Trp53) transforms neuroendocrine cells, whereas KrasG12D or BrafV600E mutations transform alveolar type 2 cells5-7. The shortest Tc consistently identified the cell of origin, regardless of mutation timing. Thus, relative Tc is a hallmark of initiation that distinguishes cancer-prone from cancer-resistant lineages in several settings, explaining how mutated cells escape transformation without inducing apoptosis, senescence or immune surveillance.© 2025. The Author(s).

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 1 区 综合性期刊
小类 | 1 区 综合性期刊
最新[2025]版:
大类 | 1 区 综合性期刊
小类 | 1 区 综合性期刊
第一作者:
第一作者机构: [1]Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada. [2]Department of Ophthalmology and Visual Science, University of Toronto, Toronto, Ontario, Canada. [3]Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. [4]Department of Ophthalmology, Research Laboratory of Ophthalmology and Vision Sciences, Eye Research Institute, West China Hospital, Sichuan University, Chengdu, China.
通讯作者:
通讯机构: [1]Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada. [2]Department of Ophthalmology and Visual Science, University of Toronto, Toronto, Ontario, Canada. [3]Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:59078 今日访问量:2 总访问量:4851 更新日期:2025-06-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号